GlassScriptPhysician profile
Matthew Michael Greiner
NPI 1942238175
$2,126.81
in general payments reported to CMS, 2019-2025
24 companies · $550 in 2025
The $550 reported for 2025 was more than what 82% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $640 · 2022: $508 · 2023: $186 · 2024: $242 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $753.22 | 2021-2024 | |
| Qol Medical, LLC | $384.59 | 2021-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $256.68 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $158.56 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.39 | 2022-2025 | Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $48.07 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $41.63 | 2024 | Airsupra |
| Medtronic, INC. | $40.96 | 2022-2024 | Interstim |
| Celltrion USA INC. | $40.41 | 2025 | Vegzelma |
| Axsome Therapeutics, INC. | $34.92 | 2024 | Auvelity |
| Mirum Pharmaceuticals, INC. | $33.17 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $30.96 | 2022 | |
| Coloplast Corp | $28.29 | 2025 | |
| Alexion Pharmaceuticals, INC. | $26.65 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $26.23 | 2025 | Bylvay |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $23.74 | 2021 | |
| Novo Nordisk INC | $18.76 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $18.27 | 2025 | Rezdiffra |
| Phadia US INC. | $18.25 | 2022 | |
| Genentech USA, INC. | $17.98 | 2024 | Xolair |
| Albireo Pharma, INC. | $16.54 | 2022 | |
| Sandoz INC. | $16.45 | 2024 | Hyrimoz |
| Pfizer INC. | $13.66 | 2021 | |
| Janssen Biotech, INC. | $13.43 | 2023 | Simponi, Simponi Aria, Remicade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Greiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.